Friday, August 14, 2020 3:46:07 PM
Channels have parallel lines. These two blue lines are converging and ultimately touch, forcing price to break upward or lower.
The pattern is a horizontal triangle. Those two lines are clearly not parallel.
If the history of the last few months repeat, price bounces off the lower blue line (which is actually floating above, and sometimes touching, SMA(100)) then goes higher until price reaches the upper blue line.
Teva is being held down by a "price fixing" law suit. Other companies (identified within that same law suit) have settled (AKA bought their way out by forking over money without admitting fault), but TEVA refuses to do that (and probably for good reason as they were just following the pricing of the other companies they were competing with).
Recent TEVA News
- Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook • Business Wire • 05/08/2024 11:00:00 AM
- Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia • Business Wire • 05/08/2024 10:30:00 AM
- Teva to Present at the 2024 Bank of America Healthcare Conference • Business Wire • 05/02/2024 10:30:00 PM
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets • Business Wire • 05/02/2024 12:30:00 PM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • Business Wire • 04/30/2024 08:00:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/30/2024 08:00:00 AM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • Business Wire • 04/16/2024 09:43:00 PM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 04/16/2024 09:30:00 PM
- Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets • Business Wire • 04/16/2024 12:00:00 PM
- Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China • Business Wire • 04/11/2024 12:30:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 • Business Wire • 04/09/2024 08:30:00 PM
- New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 • Business Wire • 04/06/2024 05:00:00 PM
- Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate • Business Wire • 04/04/2024 12:30:00 PM
- Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement • Business Wire • 04/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:27:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:24:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:08:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:46:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:43:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:39:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:35:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:30:16 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM